Research programme: cancer therapeutics - Ohara Pharmaceuticals
Latest Information Update: 13 Jan 2017
At a glance
- Originator Ohara Pharmaceutical
- Mechanism of Action Methyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myelodysplastic syndromes
Most Recent Events
- 10 Jan 2017 Preclinical trials in Myelodysplastic syndromes in Japan before January 2017 (Ohara Pharamceutical pipeline, January 2017)